



Paradoxical Expression of Ionotropic Glutamate Receptors in Leucocytes

Felix I. L. Clanchy¹ · Richard O. Williams¹ · Trevor W. Stone¹

Received: 17 October 2025 / Accepted: 10 December 2025
© The Author(s) 2026

Abstract

The expression of the ionotropic glutamate receptors AMPAR and NMDAR has been measured on circulating leucocytes, particularly CD4⁺ lymphocytes, in many studies over the last two decades. As there are agonists and antagonists for these receptors that do not cross the blood brain barrier, they represent potential new avenues to target leucocytes in human disease. To determine the range of expression across pathological conditions, we compared the expression of AMPAR and NMDAR, as well as kainate receptors and metabotropic receptors, in 12 clinical studies including inflammatory autoimmune disease (rheumatoid arthritis, juvenile idiopathic arthritis, lupus and multiple sclerosis), breast cancer, viral infection, schizophrenia and in vitro studies. We measured the expression of AMPAR and NMDAR in freshly isolated CD4⁺ T cells, stimulated PBMC and myeloid cells (HL-60, THP-1 and monocyte-derived macrophages) using TaqMan qPCR. We found the gene expression of glutamate receptors to be negligible with few exceptions. We measured low but reproducible expression of *GRIA3* in THP-1 pro-monocytic cells and human blood dendritic cell subsets (pDC, cDC1, cDC2). We observed that AMPA pre-treatment caused a greater inflammatory response in TNF-stimulated THP-1 cells. While these data illustrate a contradiction in the literature, the limited but reproducible expression of glutamate receptors in select immune subsets potentiates peripheral therapeutic targeting in specific disease contexts.

Keywords Glutamate receptors · Leucocytes · Plasmacytoid dendritic cells · TNF · Inflammation

Introduction

In the Central Nervous System (CNS), receptors for amino acids regulate neuronal excitability, synaptic transmission and the plasticity underlying behaviour. A major excitatory, depolarising compound is glutamate, which acts on receptor sub-populations characterised by the selective agonists α -amino-isoxazole-propionic acid (AMPA), N-methyl-D-aspartate (NMDA) and kainic acid; NMDA and AMPA receptors are a type of ionotropic glutamate receptor (GluR). In the CNS, NMDA receptors are unique as they

require both ligand binding and membrane depolarization to activate. This dual requirement makes NMDA receptors critical for synaptic plasticity, particularly in processes like long-term potentiation, which is essential for learning and memory. NMDA receptors are permeable to calcium (Ca²⁺), sodium (Na⁺), and potassium (K⁺) ions. The influx of Ca²⁺ through NMDA receptors triggers various intracellular signalling pathways that lead to synaptic strengthening. Additionally, NMDA receptors are involved in neurodevelopment and neuroprotection, but excessive activation can lead to excitotoxicity, contributing to neurodegenerative diseases. AMPA receptors mediate fast synaptic transmission in the central nervous system. They are primarily permeable to Na⁺ and K⁺ ions. AMPA receptors are responsible for the rapid depolarization of the postsynaptic membrane, leading to the generation of excitatory postsynaptic potentials. These receptors are crucial for the initial phase of synaptic transmission and play a role in synaptic plasticity by modulating their number and function at the synapse. In the CNS, these receptors are necessary for learning and memory, which makes them therapeutic targets for neurological

✉ Felix I. L. Clanchy
felix.clanchy@kennedy.ox.ac.uk

✉ Trevor W. Stone
trevor.stone@kennedy.ox.ac.uk

¹ Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Oxford OX3 7FY, UK

disorders. The role of these receptors in the pathophysiology of brain disorders is well-recognized and current research focuses on new therapeutic targeting approaches to ameliorate excitotoxicity [1], neurodegenerative disease [2] and neurodevelopmental disorders [3] as well as treatment for pain [4] and drug dependence [5].

AMPA receptor-targeting antagonist therapies are currently limited to Perampanel, although at one time Talampanel was considered a promising therapy [6]. Tezampanel (which is also an antagonist of kainate receptors) may also be further developed due to its neuroprotective properties [7]. A wider range of therapies exists for targeting NMDA receptors and includes ketamine, memantine and amantadine [8, 9]. The earliest identified AMPA antagonists, such as CNQX, are unsuitable treatments for neurological conditions due to poor blood brain barrier penetration. However, they may be useful for targeting AMPA receptors in non-neurological cells for, while GluRs are widely distributed on neurons around the CNS, they have also been reported on non-neuronal cells (astrocytes/microglia) and this has prompted studies to determine whether they are also expressed and functionally active on other types of immune system cells. Some of the results summarised in Table 1 lead to the conclusion that at least some of these ionotropic GluR subunits seem to be expressed at intermediate levels in leucocytes, as they are readily detectable at the protein level. As other studies have demonstrated a functional response to ionotropic GluR targeting in leucocytes, the potential to target leucocytes with agonists or antagonists for these receptors that do not cross the blood brain barrier may prove useful for treating disease. The AMPA receptor has been demonstrated to interact with the protein tyrosine kinase Lyn, which is also expressed in leucocytes, and by signalling through Lyn can modulate MAP kinase signalling [29]. Additionally, depolarisation of the membrane in lymphocytes is associated with a range of T cell phenotypes [30].

It is apparent from these studies that there is variation in the expression of receptors, which may depend on the cell type (lymphoid cells [10, 12, 18], myeloid cells [11, 26]), the species (human [10], mouse [21, 26] or rat [11, 12]) or tissue of origin (blood [10], thymus [20], bone marrow [27]), their metabolic or activation state (steady state vs disease [25]), the nature of the response examined (e.g. the response to glutamate [16]), and the sensitivity of the quantification or analytical methodology employed (e.g. PCR [10, 12] or flow cytometry [25]); see Supplementary Table 1 for further particulars. Similar findings in several laboratories indicates a degree of reproducibility, although laboratory-based factors may play a part in the variation of the results. Such factors include the limits of sensitivity using different techniques, technical factors such as the specificity of reagents (e.g. antibodies, oligonucleotides), or even the

Table 1 Key studies describing ionotropic glutamate receptors in immune cells

Citation	Gene	Protein	Reference
Ganor Y. et al. 2003	<i>GRIA3</i>	GRIA3	[10]
Dickman K.G. et al. 2003	<i>Grin1, Grin2D</i>	Grin1	[11]
Boldyrev, A.A. et al. 2004	<i>Grin1</i>		[12]
Miglio, G. et al. 2005	<i>GRIN1, GRIN2A/B/D</i>	GRIN1	[13]
Biermann, T. et al. 2007	<i>GRIN1, GRIN2B</i>		[14]
Sarchielli, P. et al. 2007	<i>GRIA3</i>	GRIA3	[15]
Kvaratskhelia, E. et al. 2009		GRIN2A/B	[16]
Sedaghati, M. et al. 2010	<i>GRIN2D, GRIN3B</i>		[17]
Mashkina, A.P. et al. 2010		GRIN1	[18]
Roozafzoon, R. et al. 2010	<i>GRIN2A, GRIN3A</i>		[19]
Affaticati, P. et al. 2011	<i>Grin1, Grin2A/B</i>	Grin1, Grin2A/B	[20]
Kahlfuß, S. et al. 2014	<i>Grin1, Grin2A/B</i>	Grin1	[21]
Bhandage, A.K. et al. 2017	<i>GRIN1, GRIN2C/D, GRIN3A/B, GRIA3/4</i>	GRIN1, GRIN2C/D	[22]
Orihara, K. et al. 2018	<i>GRIN1</i>	GRIN1	[23]
Sadat-Shirazi, M.S. et al. 2019	<i>GRIN2A/C/D, GRIN3A/B</i>		[24]
Levite M. et al. 2020		GRIN1, GRIA3	[25]
Alim, M.A. et al. 2021	<i>Grin1, Grin2A/B</i>	Grin1, Grin2A/B	[26]
Jeon H.J. et al. 2023	<i>Grin1, Grin2A/B</i>	Grin1	[27]
Torres V.O. et al. 2025	<i>Grin2A, Grin2B</i>	GRIN2A/B	[28]

limits of cell isolation which do not preclude contamination at some stage—a recognised difficulty when using amplification techniques such as PCR on bulk cell isolations.

To clarify how GluR expression, including AMPAR, NMDAR, kainate, and metabotropic receptors, differs in CD4⁺ cells between disease states and steady state, we aggregated sequencing data from multiple clinical studies and several human leucocyte subsets with differing states of activation, reasoning that these data would better demonstrate which conditions and cell types were most amenable to therapeutic targeting via each receptor class. Surprisingly, there is a substantial mismatch between the results in Table 1 and online repositories of gene expression data including The Human Protein Atlas [31] and Gene Expression Omnibus [32], which indicate that lymphocytes have virtually no expression of ionotropic glutamate receptor subunit genes.

As a common feature of gene expression measurement from Table 1 (see also Supplementary Table 1) is the use of endpoint PCR with gel electrophoresis or RT-PCR with an intercalating dye (e.g. SYBR™ Green), which can lack specificity and sensitivity, we measured the expression of the genes for individual subunits of each GluR using TaqMan qPCR assays. Most of the GluR subunit genes were not widely detected, leading to the conclusion that gene expression for most GluR subunits is generally absent from circulating leucocytes, consistent with information in the online repositories. Nevertheless, our analysis has measured low expression of three GluR subunit genes (*GRIN2D*, *GRIN3B*, *GRIA3*) in the pro-monocytic THP-1 cell line and one AMPA receptor subunit GluA3 (gene *GRIA3*) in plasmacytoid cells (pDCs).

Methods and Materials

Analysis of Clinical Studies

Relevant studies archived at Gene Expression Omnibus[32] were collated and the relative gene expression (normalised transcripts per million, TPM) in leucocytes were compiled for 4 classes of GluRs – AMPA and NMDA ionotropic receptors as well as kainate receptors and metabotropic receptors. Additionally, 3 genes that are not typically expressed in lymphocytes (*IRAK3*, *IDO1*, *CSF1R*), THP-1 cells (*DNTT*, *CD3E*, *LAG3*) or pDC (*IRAK3*, *TDO2*, *DNTT*) were also included as an indicator of background or non-specific expression.

Human Leucocytes

Aphaeresis cones from healthy donors were obtained from the NHS Blood Service in accordance with approval from the Fulham Research Ethics Committee (11/H0711/7). Aphaeresis material was diluted with PBS to ~90 mL and layered over Lympholyte®-H (Human) Cell Separation Media (Cedarlane) and separated by centrifugation at 20 °C at 2000 rpm for 20 min, without brake. The PBMC were isolated by aspiration and washed twice with PBS by centrifuging at 1500 rpm at 4 °C for 5 min. CD4⁺ lymphocytes were isolated from PBMC by firstly depleting CD14⁺ monocytes by positive selection (CD14 microbeads, Miltenyi 130–050–201) and then positively selecting CD4⁺ cells (CD4 microbeads, Miltenyi 130–045–101) from the CD14[−] cells. Blood dendritic cells (pDC, cDC1, cDC2) were isolated from PBMC firstly by negative selection of non-DC (Pan-DC Enrichment Kit, Miltenyi 130–100–777) then staining the isolated cells for FACS with antibodies for CD19, CD1c, CD141, CD303 and viability (Zombie Violet™

Fixable Viability kit); all antibodies and viability dye were from BioLegend (302215, 331505, 344105, 354207 and 423113, respectively). From the enriched starting population, DC subsets were flow sorted as singlet, live, CD19[−] cells and then further divided into pDC (CD1c[−]CD303⁺), cDC1 (CD141⁺CD303[−]) or cDC2 (CD1c⁺CD303[−]); blood DC subsets were washed with PBS and snap frozen for RNA extraction. Additionally, the THP-1 pro-monocytic and HL-60 pro-myelocytic cell lines were also used for a transcriptomic analysis of ionotropic GluR expression; the DBTRG glial cell line was used for comparison.

Human Monocyte-Derived Macrophages (MDM)

Human MDM were derived as previously described[33]. Briefly, monocytes were isolated from PBMC using immunomagnetic CD14 positive selection beads and columns (CD14 microbeads, Miltenyi 130–050–201). Macrophages were differentiated from monocytes for 5 days in 10% FBS 1% Penicillin/Streptomycin RPMI (10⁷ cells/10 mL/10 cm dish) supplemented with 50 ng/mL M-CSF (Peprotech, 300–25); MDM were detached and re-plated into 6-well plates, rested overnight, then stimulated with M1-polarising (LPS (10 ng/mL, Merck L6529) and IFN γ (10 ng/mL, Peprotech 300–02)) or M2-polarising (IL-4 (50 ng/mL, Peprotech 200–04)) stimuli; prior to stimulation, some macrophages were collected as a pre-treatment condition. After 20 h of stimulation, cells were washed with PBS then harvested for RNA extraction.

RNA Extraction and Reverse Transcription

RNA extraction was performed with a Total RNA miniprep kit (New England Biolabs, T2010S) including the DNase I on-column digestion, according to the manufacturer's protocol. Reverse transcription of 500 ng of RNA was performed with the High Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific, 4368814) in a 40 μ L reaction, which was then diluted to a total of 120 μ L with RNase-free water.

PCR

For THP-1 pretreated with AMPA then stimulated with TNF, gene expression was measured with TaqMan™ Array Human Immune Panel microfluidics cards (Fisher Scientific) on a Vii7 real-time PCR system. Seven potential housekeeping genes were measured for each sample (*HPRT1*, *PGK1*, *GUSB*, *TFRC*, *ACTB*, *GAPDH* and *18S*). As the variation and range for the Ct of *HPRT1* was less than a third of the alternatives, it was chosen as the housekeeping gene used for analyses using the $\delta\delta$ CT approximation method. For

GluR subunit gene expression, TaqMan quantitative PCR (qPCR) was performed in a reaction of 6 μ L containing 2.4 μ L of template (equivalent to 10 ng of RNA). TaqMan assays were from ThermoFisher Scientific and as follows – *GRIN1* (Hs00609557_m1), *GRIN2A* (Hs00168219_m1), *GRIN2B* (Hs01002012_m1), *GRIN2C* (Hs01016628_m1), *GRIN2D* (Hs00181352_m1), *GRIN3A* (Hs01077968_m1), *GRIN3B* (Hs00879911_g1), *GRIA1* (Hs00181348_m1), *GRIA2* (Hs00181331_m1), *GRIA3* (Hs01557466_m1), *GRIA4* (Hs00898778_m1), *KCNA3* (Hs00704943_s1) and *HPRT1* (Hs02800695_m1). Expression was measured relative to housekeeper gene expression (*HPRT1*) using the $\delta\delta$ CT approximation method.

For the measurement of flip/flop isoforms of *GRIA3* in pDC and THP-1 cells, the template of each reaction was 8.32 and 4.16 ng, respectively, in a total reaction volume of 10.5 μ L consisting of 5.25 μ L of MangoMix™ (Meridian Bioscience, BIO-25033), water and primers; primers for *GRIA3* isoforms were Flip_F GGAATGTGGAGCCA AGGACT, Flop_F ATGAGCAAGGCCTCTTGGAC and Flip+Flop_R TTGAAGCAGCCACGTTTTTCG. For each isoform, a PCR positive control template plasmid was created by traditional cloning methods; water alone was used as negative control. PCR reactions were run on a TAE gel containing 1.5% agarose (Meridian Bioscience, BIO-41025) alongside a DNA ladder (Hyper Ladder™ 1 kb, Meridian Bioscience, BIO-33053). Standard curve qPCR was performed as previously described [34, 35].

Transcriptomic Response to AMPA

THP-1 cells were cultured in 10% FBS 1% P/S RPMI in 6 well plates (2×10^6 /well). Cells were pretreated with vehicle or AMPA (Abcam (ab120130)) for 1 h then stimulated with TNF (5 ng/mL, Peprotech, 300-01A) for 6 h. Cells were washed with PBS and snap frozen for RNA extraction.

Statistics

Results were analysed with MS Excel (Microsoft) or Graphpad Prism (GraphPad Software). Heatmaps and dendrograms were drawn with Multi-Experiment Viewer [36] or RAWGraphs [37]. Statistical tests are outlined in Figure Legends.

Results

Over the previous two decades, many researchers have reported that lymphocytes, particularly CD4⁺ T cells, express intermediate levels of ionotropic GluRs (Table 1, Supplementary Table 1) and also, using single cell analyses

(FACS, ICC/IHC), indicate that a significant proportion of T cells have detectable expression at the protein level [10, 22, 23, 27]. Additionally, several researchers have measured functional responses in cells to ligands of these receptors. However, RNA sequencing data from several studies indicates that the level of gene expression in these cells, is negligible (Fig. 1, Supplementary Table 2); this is apparent in either healthy controls or patients with a myriad of health conditions (autoimmune arthritis, lupus, multiple sclerosis, cancer, viral infection and schizophrenia), and in naïve or stimulated conditions; additionally, there was also negligible expression on mast cells [38, 39], which have the capacity to express CD4 [40, 41]. A comparison of naïve and activated lymphocytes (CD4⁺/CD8⁺) revealed no substantial levels or difference in expression [42]. In many instances, the level of expression of genes that are not typically expressed in CD4⁺ lymphocytes, or at least the great majority, (*IRAK3*, *IDO1*, *CSF1R*) are greater or equivalent to the very low levels seen for most GluRs. Across all samples, *GRIN3B* expression was consistently higher than other genes, but present at very low levels.

To validate this observation, we measured the expression of the genes for AMPA and NMDA receptor subunits (Fig. 2) in a range of leucocytes, by TaqMan qPCR. As there is substantial literature supporting the expression of these molecules in unstimulated, circulating CD4⁺ T cells, we measured expression in these cells, as well as PBMC that were freshly isolated or stimulated with anti-CD3 or LPS for either 6 h or 20 h (Fig. 2a); the expression of *KCNA3* was also measured as a non-ionotropic receptor, the activity of which is modulated by glutamate. The C_t values of AMPA/NMDA receptor subunit qPCRs were very high (typically more than 35 cycles) indicating very low expression, and for some subunits (e.g. *GRIA1*, *GRIN2C*) no amplification was observed. A similar pattern of gene expression was observed for myeloid cells (Fig. 2b), however for some subunits (*GRIN2D*, *GRIN3B*, *GRIA3*), expression was sufficient to perform $\delta\delta$ CT analysis. For the three genes expressed, the pro-monocytic THP-1 cell line had low but reproducible expression that was higher than HL-60 cells or human MDM (Fig. 2c).

Given the low expression in CD4⁺ lymphocytes, it was hypothesized that another, less-prevalent cell type may be contributing to the gene expression observed in several studies where less stringent isolation techniques were used. *GRIA3* expression was undetectable in circulating CD14^{hi}CD16⁻ classical human monocytes and negligible ($C_t \approx 35$) in circulating CD34⁺ haematopoietic precursors (data not shown, $n=5$ healthy donors for both). To further explore the possibility that non-lymphoid leucocytes may have contaminated previous studies of PBMC-derived cells, blood DC were isolated and gene expression for GluR was




Fig. 1 Expression of glutamate receptor subunits in lymphocytes in clinical studies. Expression of NMDA (*GRIN*) and AMPA (*GRIA*) GluR, kainate (*GRIK*) and metabotropic (*GRM*) GluR subunit genes from 10 clinical studies and 2 basic research studies. *IRAK3*, *IDO1*


and *CSF1R* gene expression indicates genes not typically expressed by lymphoid cells. TPM, transcripts per million. See Supplementary Table 2 for further particulars

measured. *GRIN1*, *GRIN3B*, *GRIA1-4* expression was measured in human circulating DC subsets (pDC, cDC1, cDC2). In pDC, *GRIA3* was the only detectable AMPA receptor detected (Fig. 2d and e); we did not detect *GRIA1*, *-2* or *-4* in pDC (data not shown).

AMPA subunits have isoforms, known as flip or flop isoforms, which form receptors that have differing trafficking and depolarisation kinetics in nerve cells [43–45]. When measured, the THP-1 cells and pDC expressed the flip but not the flop isoforms of *GRIA3* (Fig. 2f and g). The

expression of GluRs was investigated in 9 studies of THP-1 cells (Fig. 3) and 7 studies of pDC, (Fig. 4) and found to be broadly in line with our results; the 2 studies that included primary human macrophage-lineage cells [46, 47] had lower levels of GluR expression compared to THP-1 cells. As the THP-1 cells appeared to express at least one type of AMPA subunit, we measured the transcriptomic response of AMPA on TNF stimulation in these cells (Fig. 5, Supplementary Fig. 1); the inflammatory response to TNF was upregulated by AMPA stimulation.

Fig. 2 Ionotropic GluR gene expression in leucocytes is negligible. Ct values for GluR were measured in (A) healthy donor CD4⁺ lymphocytes and PBMC stimulated with LPS or anti-CD3 for 6 or 20 h or (B) myelomonocytic cells (HL60), promonocytic cells (THP-1), differentiated monocyte-derived macrophages and the DBTRG glial cell-line; the expression of *KCN A3* was measured as a positive control. (C) Relative gene expression for *GRIN2D*, *GRIN3B* and *GRIA3* was determined in HL60, THP-1 and macrophages (PRE-polarisation, M1 (IFN γ /LPS), M2 (IL-4)) using *HPRT1* as a house-keeping gene. (D) Quantitative Ct values for *GRIN1*, *GRIN3B*, *GRIA3* in unstimulated blood DC subsets from healthy donors; relative gene expression for *GRIN1*, *GRIN3B* and *GRIA3* was determined (E). Flip and Flop isoforms of *GRIA3* were detected by PCR in (F) THP-1 cells and (G) plasmacytoid DC. (F) THP-1 ($n=4$), positive controls (PC) for *GRIA3* Flop and Flip isoforms and negative control (NC); L, ladder. (G) pDC ($n=3$ donors), PC for Flop and Flip and NC; non-specific band (NS) is indicated. (A-E) values are mean \pm SEM for (A) $n=3$ donors, (B, C) $n=3$ donors (M ϕ) or $n=4$ (HL60, THP-1, DBTRG), (D, E) $n=3$ donors






Fig. 3 Expression of glutamate receptor subunits in THP-1 cells. Expression of NMDA (GRIN) and AMPA (GRIA) GluR, kainate (GRIK) and metabotropic (GRM) GluR subunit genes from 11 basic research studies involving THP-1 and monocytic/macrophage cells.

DNTT, *CD3E* and *LAG3* indicate genes not typically expressed in monocytic/macrophage cells. TPM, transcripts per million. See Supplementary Table 3 for further particulars

Discussion

The Paradox of Expression

There are several potential explanations for the differences between measurements of GluR expression. Firstly, for the measurement of gene expression in isolated cells, the methods of isolation may result in different purities of cells or the composition of subsets within the total population may change. Several studies have made use of the propensity of monocytes to adhere to tissue culture plastic to deplete them from PBMC [10, 13, 15, 16, 18] in combination with other methods of isolation. Other studies relied

upon density separation to isolate lymphocytes [12, 17–19, 22, 24]. It is possible that isolation methods with a higher level of stringency, while more costly and time consuming, would provide greater certainty of gene expression in the cells intended to be isolated for PCR analysis. This is evident in the data from clinical studies where density separation alone [48] or CD4 positive selection without prior depletion of CD14⁺ monocytes (which express low levels of CD4) [49] have higher expression of non-lymphoid genes (*IRAK3*, *IDO1*, *CSF1R*) compared to studies using negative isolation or flow sorting [50, 51].

Secondly, the amount of template used for PCR detection of genes has some bearing on the capacity to detect and




Fig. 4 Expression of glutamate receptor subunits in pDC cells. Expression of NMDA (GRIN) and AMPA (GRIA) GluR, kainate (GRIK) and metabotropic (GRM) GluR subunit genes from 7 pDC studies. *IRAK3*,

TDO2 and *DNTT* indicate genes not typically expressed in pDC. TPM, transcripts per million. See Supplementary Table 4 for further particulars

measure the gene. In the current study, we used the equivalent of 10 ng of RNA per reaction and measured very little or no expression for some genes; in some of the literature, the template required for detection is significantly higher with 100 ng, 400 ng or 2 µg of template used per reaction [10, 13, 17]. To some degree, the use of gel electrophoresis to measure the PCR may necessitate an increase in the amount of PCR template, though this method has the drawback of being less quantitative than qPCR as it measures the PCR end product. We have previously used linearised plasmids containing sequences specific for standard curve qPCR using TaqMan assays [34, 35] and determined that a Ct value of ~30 is equivalent to 100 copies of template per reaction, or 1 copy per 10 cells using the estimation of 10 pg per cell [52] and 10 ng equivalent of RNA per qPCR reaction (see Supplementary Fig. 2). Although the amount of RNA per cell will vary according to cell type and activation status, our data is in broad agreement with the sequencing data. Regardless of the amount of template used to detect GluR gene expression, the relatively higher expression of ‘non-canonical’ genes indicates GluR gene expression is very low.

Finally, the mismatch between nucleic acid or protein expression and apparent functional responses in leucocytes may possibly arise when there are sub-optimal tools (such

as antibodies), analytical methodology, control reagents or the use of different cell types, sources, and storage. It is, therefore, important to consider whether there could be another explanation. For example, the reported functional effects of ligands might be mediated by molecular targets which are distinct from the those on neurons. In addition, many genes may be present at extremely low levels normally, but which could be induced to produce a disproportionate amount of protein [53]. One unlikely possibility is the substantial potential for ‘molecular crosstalk’ generated by the movement and exchange of nucleic acids and proteins between cells. Molecular transfers could involve exocytosis and endocytosis, extracellular vesicles or nanotubes, in addition to the uptake of molecules resulting from cell damage or disruption. Such intercellular exchanges might explain the apparent presence of ‘foreign’ proteins in leucocytes lacking the necessary intrinsic transcriptional expression. This concept of macromolecule secretion and uptake has been specifically proposed as an important factor in the frequently observed mismatch between gene and protein expression [53].

A further point of doubt is that the concentration of glutamate in the blood is 10–100 µM [54, 55], whereas in the extracellular fluid of the brain it is 0.5–2.5 µM [56] and less than 0.4 µM is reported for cerebrospinal fluid [57]. Given




Fig. 5 AMPA increases the expression of inflammatory mediators in TNF-stimulated monocytic cells. Heat map of gene expression in THP-1 cells pre-treated with AMPA (50 μ M) or vehicle (1 h) then stimulated with TNF (5 ng/mL, 6 h); $n=3$. See Supplementary Fig. 1 for expanded data

that the reported proportion of leucocytes expressing GluRs was measured by surface staining flow cytometry from as low as 5% [13] to ~20% [22, 25], ~35% [23] or ~75% (vs a control stain of ~13% [10]), some thought must be given to understanding which mechanism prevents the potential continuous transfer of ions via the GluR channels due to the canonical ligand being present at a concentration of up to 2 orders of magnitude greater than in the brain; the presence of 20 mg/mL (136 μ M) of glutamate in Roswell Park Memorial Institute 1640 medium (RPMI), which is commonly used for leucocyte cell culture, might also trigger significant ion transfer.

Although our analysis of GluR in different cell types and disease conditions did not reveal disease associations but rather a near absence of expression for most GluR subunit gene expression, comparing datasets from different clinical studies provides a framework for elucidating pathological mechanisms and identifying disease-specific biomarkers. This strategy can help to validate findings across independent populations but also enhance reproducibility, enabling the discovery of clinically relevant biomarkers and mechanistic insights that single-study analyses might miss.

The Relevance of pDCs to Neuroimmunology

The presence of cDCs and pDCs in the CNS has been recognised for some years [58–61]. Although there are few DCs present in the normal, uninjured CNS parenchyma, migrations occur if there is local damage from an injury or stroke, or during peripheral inflammation, infections or exposure to stress. One consequence of the increased blood levels of cytokines and chemokines in these cases is an increased permeability of the blood–brain barrier, allowing access of leucocytes to the CNS including cDCs and pDCs, with increased entry also of myeloid cells.

In the example of cerebral ischaemia, activated microglia attract the movement of DCs into the brain parenchyma, including cDCs and pDCs [62]. The pDCs are especially important in combatting viral infections since their differentiation is promoted by viral contact. As a result, MHC class I and class II proteins are induced, along with surface membrane molecules involved in T cell activation such as CD80 and CCR7. Their persistence for long periods after inflammation [63–65] reflects their neuroprotective activity. Indeed, the entry of pDCs into the CNS has been associated

with reducing local inflammation, thus improving the progression and outcome from disorders such as multiple sclerosis (MS) and its rodent equivalent (experimental autoimmune encephalitis, EAE) [66, 67]. Subpopulations of cDCs are required for the generation of T cells protective against progressive inflammation in the CNS [68, 69]. The role of pDCs may then become pivotal since the IFN- β produced by them will contribute to the further influx of cDCs [70] and their promotion of Treg differentiation. The trafficking of pDCs is regulated partly by microRNA species [71] and chemokines such as CCL17 [72], with recruitment to the CNS enhanced in the early stages of EAE [73]; cytoskeletal changes are also involved [74].

GluR activation on pDCs may exert dual effects on immune regulation depending on signalling pathways. Activation can enhance type I interferon production and promote antitumor immunity, while chronic signalling might induce tolerogenic phenotypes that facilitate tumour escape or exacerbate autoimmune inflammation [75]. These context-dependent outcomes require a refined understanding of receptor subtype-specific roles and the influences of the inflammatory milieu before considering GluRs as therapeutic targets [76, 77].

GluA3 Subunits

In addition to their expression in neurons and glia in the CNS, individual AMPAR GluA3 subunits (*GRIA3*) are present in some non-neuronal sites such as cardiac, pancreatic, endothelial and tumour cells [78–82]. GluA3 is one of the few GluR subunits whose expression is increased by anti-inflammatory steroids, which is consistent with an immune-related activity [83]. Expression is, however, normally associated with the expression of other AMPAR subunits, especially GluA2 (*GRIA2*), where GluA3 has a significant influence on synaptic speed, promoting vesicle release and plasticity [84]. Increased levels of cyclic AMP increase the conductance of GluA3-operated channels, leading to a potentiation of transmission [85].

It has been demonstrated that all four AMPAR subunits (GluA1–4) can assemble into homomeric or heteromeric receptors when experimentally generated in appropriate cells [86–99]. However, there is preferential incorporation of GluA2 into the tetramer [99–101] and this subunit differs from the others as its incorporation renders the receptor Ca²⁺ impermeable, more stable and better able to traffic to the neuronal synapse [102]; essentially, the structural flexibility of GluA3 predisposes it to interact preferentially with other AMPAR subunits [101, 103] and, as a result, GluA3 homomers can only form in significant numbers in the absence of other subunits [94, 104, 105]. To our knowledge this is the first observation of GluA3 subunits occurring

naturally in the absence of GluA2 subunits in pDC. Their expression and functional activity in pDCs may have substantial clinical implications for immunological disorders.

It is possible that glutamate itself is the major endogenous ligand for homomeric GluA3 receptors in pDCs, as it is for homomeric GluA1 combinations [106, 107]. Glutamate is released by lymphocytes such as Th17 cells in response to activation by β 1-integrin and potassium channel activation, and by DCs in the process of T cell activation [108]. Similarly, glutamate activates Kv1.3 potassium channel opening, leading to increased T cell activity [109]. Since the primary role of glutamate in the CNS is the regulation of excitability, this may also contribute to its effects on leucocytes. Indeed, regulation of DC polarisation seems to represent an important form of intercellular communication since the membrane potential of cDCs is influenced by the activation of sensory receptors such as nociceptors [110, 111].

The Flip-flop Balance

An additional novel property displayed by the GluA3 subunits observed here is that they are predominantly in the ‘flip’ conformation. In excitable cells generally, especially neurons, the flip and flop phenotypes regulate channel open time, with the flop form exhibiting greater flexibility, reducing channel open time and having fast desensitisation kinetics [112–114]. In neurons, changes in the flip-flop ratio are dependent on neuronal activity, being a recognised mechanism of feedback control of excitability and plasticity in neurons and in other cell types including HEK293 [115] or *Xenopus* oocytes [90, 116]. Expression is also dependent on neuronal type, exemplified by the presence of flop forms primarily in small interneurons, whereas larger pyramidal projection neurons express mainly the flip variant [45, 117–123]. A shift from largely flip to flop forms occurs early in development [43, 118, 124]. This change may occur together with the phosphorylation of Lyn, a component of the transduction pathways activated by AMPAR activation, which leads to the activation of MAPK and the expression of Brain Derived Neurotrophic Factor (BDNF), a key factor in early neuronal development [29].

Conclusions

The subunit which stands out in our analysis is the GluA3 protein (gene *GRIA3*), a subunit of the AMPA receptor group which we have now examined in more detail. Our data suggest that this subunit is functionally active on THP-1 cells and has clinical implications for several immunological disorders and, as THP-1 cells are a leukaemia cell-line, the potential for further translational research in related

disorders. GluR involvement in acute myeloid leukaemia [125] and chronic myelogenous leukaemia [126, 127] has been observed, which may in part be due to pro-survival signals associated with this class of receptors [128]. We have used comparative analyses to demonstrate that the level of gene expression is far below what would be expected from the levels of protein measured in numerous reports, and have demonstrated that the level of gene expression is often very low or undetectable by qPCR or, as seen in many datasets, if detectable then below the level of expression of genes that would not normally be expressed in the cell type analysed. The paradox of negligible gene expression of AMPA and NMDA receptors versus the intermediate protein expression reported, and the implications for this level of expression in the circulation where the concentration of glutamate is relatively high, will require a better understanding of the role of amino acid receptors in leucocytes.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s12016-025-09126-2>.

Acknowledgements We wish to acknowledge the assistance of Jonathan Webber for flow sorting and management of the Kennedy Institute flow cytometry facility.

Author Contributions All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Study conception and design - all authors. Acquisition of data - FILC. Analysis and interpretation of data - FILC.

Funding Epsom Medical Research (EMR22) and MASTERSWITCH (Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices), EU 7th Framework Programme (223404).

Data Availability The data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher. Sequencing data can be accessed at Gene Expression Omnibus using appropriate GEO accession numbers.

Declarations

Ethics Approval Human tissues were collected in compliance with ethical approval (11/H0711/7 Fulham Research Ethics Committee).

Conflict of Interest The authors declare no competing interests.

Competing Interests The authors have no competing interests to declare that are relevant to the content of this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not

included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Chamorro Á et al (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. *Lancet Neurol* 15(8):869–881
2. Ning L et al (2024) AMPA receptors in Alzheimer disease: pathological changes and potential therapeutic targets. *J Neuropathol Exp Neurol* 83(11):895–906
3. Salpietro V et al (2019) AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. *Nat Commun* 10(1):3094
4. Wang Y et al (2010) Regulation of AMPA receptors in spinal nociception. *Mol Pain* 6:5
5. Hrickova M, Ruda-Kucerova J (2025) Do AMPA/kainate antagonists possess potential in the treatment of addiction? Evidence from animal behavioural studies. *Prog Neuropsychopharmacol Biol Psychiatry* 138:111355
6. Langan YM et al (2003) Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. *Epilepsia* 44(1):46–53
7. Pulkrabkova L et al (2023) Neurotoxicity evoked by organophosphates and available countermeasures. *Arch Toxicol* 97(1):39–72
8. Glasgow NG et al (2017) Memantine and ketamine differentially alter NMDA receptor desensitization. *J Neurosci* 37(40):9686–9704
9. Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. *J Neurosci* 25(13):3312–3322
10. Ganor Y et al (2003) Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. *J Immunol* 170(8):4362–4372
11. Dickman KG et al (2004) Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity. *Am J Respir Cell Mol Biol* 30(2):139–144
12. Boldyrev AA et al (2004) Rodent lymphocytes express functionally active glutamate receptors. *Biochem Biophys Res Commun* 324(1):133–139
13. Miglio G, Varsaldi F, Lombardi G (2005) Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. *Biochem Biophys Res Commun* 338(4):1875–1883
14. Biermann T et al (2007) Dopamine and N-methyl-D-aspartate receptor expression in peripheral blood of patients undergoing alcohol withdrawal. *J Neural Transm (Vienna)* 114(8):1081–1084
15. Sarchielli P et al (2007) Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. *J Neuroimmunol* 188(1–2):146–158
16. Kvaratskhelia E et al (2009) N-methyl-D-aspartate and sigma-ligands change the production of interleukins 8 and 10 in lymphocytes through modulation of the NMDA glutamate receptor. *NeuroImmunoModulation* 16(3):201–207
17. Sedaghati M et al (2010) Expression of NR3B but not NR2D subunit of NMDA receptor in human blood lymphocytes can serve as a suitable peripheral marker for opioid addiction studies. *Eur J Pharmacol* 633(1–3):50–54

18. Mashkina AP et al (2010) NMDA receptors are expressed in lymphocytes activated both in vitro and in vivo. *Cell Mol Neurobiol* 30(6):901–907
19. Roozafzoon R et al (2010) Expression of NMDA receptor subunits in human peripheral blood lymphocytes in opioid addiction. *Eur J Pharmacol* 638(1–3):29–32
20. Affaticati P et al (2011) Sustained calcium signalling and caspase-3 activation involve NMDA receptors in thymocytes in contact with dendritic cells. *Cell Death Differ* 18(1):99–108
21. Kahlfuß S et al (2014) Immunosuppression by N-methyl-D-aspartate receptor antagonists is mediated through inhibition of Kv1.3 and KCa3.1 channels in T cells. *Mol Cell Biol* 34(5):820–831
22. Bhandage AK et al (2017) AMPA, NMDA and kainate glutamate receptor subunits are expressed in human peripheral blood mononuclear cells (PBMCs) where the expression of GluK4 is altered by pregnancy and GluN2D by depression in pregnant women. *J Neuroimmunol* 305:51–58
23. Orihara K et al (2018) Neurotransmitter signalling via NMDA receptors leads to decreased T helper type 1-like and enhanced T helper type 2-like immune balance in humans. *Immunology* 153(3):368–379
24. Sadat-Shirazi MS et al (2019) NMDA receptors of blood lymphocytes anticipate cognitive performance variations in healthy volunteers. *Physiol Behav* 201:53–58
25. Levite M et al (2020) Dual-targeted autoimmune sword in fatal epilepsy: patient's glutamate receptor AMPA GluR3B peptide autoimmune antibodies bind, induce reactive oxygen species (ROS) in, and kill both human neural cells and T cells. *J Autoimmun* 112:102462
26. Alim MA et al (2021) Glutamate triggers the expression of functional ionotropic and metabotropic glutamate receptors in mast cells. *Cell Mol Immunol* 18(10):2383–2392
27. Jeon HJ et al (2023) N-methyl-D-aspartate receptors induce M1 polarization of macrophages: feasibility of targeted imaging in inflammatory response in vivo. *Cell Biosci* 13(1):69
28. Torres VO et al (2025) B cells upregulate NMDARs, respond to extracellular glutamate, and express mature BDNF to protect the brain from ischemic injury. *Neurobiol Dis* 207:106819
29. Hayashi T et al (1999) The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. *Nature* 397(6714):72–76
30. Robert V et al (2011) Calcium signalling in T-lymphocytes. *Biochimie* 93(12):2087–2094
31. Sjöstedt E et al (2020) An atlas of the protein-coding genes in the human, pig, and mouse brain. *Science*. <https://doi.org/10.1126/science.aay5947>
32. Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res* 30(1):207–210
33. Clanchy FIL et al (2022) Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression. *J Autoimmun* 128:102810
34. Clanchy FIL et al (2021) Tlr expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis. *J Autoimmun* 118:102597
35. Clanchy FIL, Williams RO (2019) Ibudilast inhibits chemokine expression in rheumatoid arthritis synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis. *Arthritis Rheumatol* 71(5):703–711
36. Saeed AI et al (2003) TM4: a free, open-source system for microarray data management and analysis. *Biotechniques* 34(2):374–378
37. Mauri M et al. (2017) RAWGraphs: A visualisation platform to create open outputs, in proceedings of the 12th Biannual conference on Italian SIGCHI Chapter. Association for computing machinery: Cagliari, Italy. Article 28
38. Leveque E et al (2024) Alternative activation of mast cells by CD4+ T helper cells. *J Leukoc Biol* 116(5):1127–1141
39. Battut L et al (2024) IL-33-primed human mast cells drive IL-9 production by CD4(+) effector T cells in an OX40L-dependent manner. *Front Immunol* 15:1470546
40. Li Y et al (2001) Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4. *Blood* 97(11):3484–3490
41. Soilleux EJ, Bowling J, Hollowood K (2009) CD4 expression by mast cells in mastocytosis: a case report. *J Clin Pathol* 62(6):564
42. Bediaga NG et al (2021) Multi-level remodelling of chromatin underlying activation of human T cells. *Sci Rep* 11(1):528
43. Monyer H, Seeburg PH, Wisden W (1991) Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. *Neuron* 6(5):799–810
44. Partin KM, Bowie D, Mayer ML (1995) Structural determinants of allosteric regulation in alternatively spliced AMPA receptors. *Neuron* 14(4):833–843
45. Coleman SK et al (2006) Isoform-specific early trafficking of AMPA receptor flip and flop variants. *J Neurosci* 26(43):11220–11229
46. Bianchetto-Aguilera F et al (2020) Deciphering the fate of slan(+) -monocytes in human tonsils by gene expression profiling. *FASEB J* 34(7):9269–9284
47. Sauer J et al (2024) Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells. *Front Immunol* 15:1232070
48. Gatta E et al (2021) Concordance of immune-related markers in lymphocytes and prefrontal cortex in schizophrenia. *Schizophr Bull Open* 2(1):sgab002
49. Salehi Z et al (2021) RNA sequencing of CD4(+) T cells in relapsing-remitting multiple sclerosis patients at relapse: deciphering the involvement of novel genes and pathways. *J Mol Neurosci* 71(12):2628–2645
50. Takeshita M et al (2019) Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell. *Ann Rheum Dis* 78(10):1346–1356
51. Inamo J et al (2021) Molecular remission at T cell level in patients with rheumatoid arthritis. *Sci Rep* 11(1):16691
52. Russo J, Russo IH (2014) Techniques and methodological approaches in breast cancer research. Springer, New York
53. Jiang L et al (2020) A quantitative proteome map of the human body. *Cell* 183(1):269–283.e19
54. Schielke GP, Betz AL (1992) Electrolyte transport, in physiology and pharmacology of the blood-brain barrier, M.W.B. Bradbury, Editor. Springer Berlin Heidelberg: Berlin, Heidelberg. p 221–243
55. Ferrari A et al (2009) Effective prophylactic treatments of migraine lower plasma glutamate levels. *Cephalalgia* 29(4):423–429
56. Bogdanov MB, Wurtman RJ (1994) Effects of systemic or oral ad libitum monosodium glutamate administration on striatal glutamate release, as measured using microdialysis in freely moving rats. *Brain Res* 660(2):337–340
57. Ferrarese C et al (1993) Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. *Ann Neurol* 33(3):316–319
58. Pashenkov M et al (2001) Two subsets of dendritic cells are present in human cerebrospinal fluid. *Brain* 124(Pt 3):480–492
59. Serafini B et al (2006) Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. *J Neuropathol Exp Neurol* 65(2):124–141
60. Zozulya AL et al (2010) The role of dendritic cells in CNS autoimmunity. *J Mol Med (Berl)* 88(6):535–544

61. Yogev N et al (2012) Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells. *Immunity* 37(2):264–275
62. Gallizioli M et al (2020) Dendritic cells and microglia have non-redundant functions in the inflamed brain with protective effects of type 1 cDCs. *Cell Rep* 33(3):108291
63. Bossù P et al (2015) Myeloid dendritic cells are potential players in human neurodegenerative diseases. *Front Immunol* 6:632
64. Clarkson BD et al (2014) Mapping the accumulation of co-infiltrating CNS dendritic cells and encephalitogenic T cells during EAE. *J Neuroimmunol* 277(1–2):39–49
65. Clarkson BD et al (2015) Ccr2-dependent dendritic cell accumulation in the central nervous system during early effector experimental autoimmune encephalomyelitis is essential for effector T cell restimulation in situ and disease progression. *J Immunol* 194(2):531–541
66. Duraes FV et al (2016) pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation. *J Autoimmun* 67:8–18
67. Bailey SL et al (2007) CNS myeloid DCs presenting endogenous myelin peptides “preferentially” polarize CD4+ T(H)-17 cells in relapsing EAE. *Nat Immunol* 8(2):172–180
68. Mundt S et al (2019) Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation. *Sci Immunol* 4(31):eaau8380
69. Giles DA et al (2018) CNS-resident classical DCs play a critical role in CNS autoimmune disease. *J Clin Invest* 128(12):5322–5334
70. Pennell LM, Fish EN (2017) Interferon- β regulates dendritic cell activation and migration in experimental autoimmune encephalomyelitis. *Immunology* 152(3):439–450
71. Hoye ML et al (2018) MicroRNA signature of central nervous system-infiltrating dendritic cells in an animal model of multiple sclerosis. *Immunology* 155(1):112–122
72. Ruland C et al (2017) Chemokine CCL17 is expressed by dendritic cells in the CNS during experimental autoimmune encephalomyelitis and promotes pathogenesis of disease. *Brain Behav Immun* 66:382–393
73. Sie C et al (2019) Dendritic cell accumulation in the gut and central nervous system is differentially dependent on $\alpha 4$ integrins. *J Immunol* 203(6):1417–1427
74. Meena M et al (2021) Transmigration across a steady-state blood-brain barrier induces activation of circulating dendritic cells partly mediated by actin cytoskeletal reorganization. *Membranes (Basel)* 11(9):700
75. Monti M et al (2024) Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling. *J Exp Clin Cancer Res* 43(1):196
76. Yang L et al (2023) Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity. *Cancer Biol Med* 20(10):728–747
77. Zhou B, Lawrence T, Liang Y (2021) The role of plasmacytoid dendritic cells in cancers. *Front Immunol* 12:749190
78. Weaver CD et al (1996) Differential expression of glutamate receptor subtypes in rat pancreatic islets. *J Biol Chem* 271(22):12977–12984
79. Bertrand G et al (1993) Glutamate stimulates glucagon secretion via an excitatory amino acid receptor of the AMPA subtype in rat pancreas. *Eur J Pharmacol* 237(1):45–50
80. Gutiérrez-Igarza K et al (1996) Localization of AMPA-selective glutamate receptor subunits in the adult cat visual cortex. *Vis Neurosci* 13(1):61–72
81. Jacob AL, Weinberg RJ (2015) The organization of AMPA receptor subunits at the postsynaptic membrane. *Hippocampus* 25(7):798–812
82. van der Spek SJF et al (2022) Expression and interaction proteomics of GluA1- and GluA3-subunit-containing AMPARs reveal distinct protein composition. *Cells* 11(22):3648
83. Soltani A et al (2023) A narrative review of the effects of dexamethasone on traumatic brain injury in clinical and animal studies: focusing on inflammation. *Inflammopharmacology* 31(6):2955–2971
84. Antunes FM, Rubio ME, Kandler K (2020) Role of GluA3 AMPA receptor subunits in the presynaptic and postsynaptic maturation of synaptic transmission and plasticity of endbulb-bushy cell synapses in the Cochlear Nucleus. *J Neurosci* 40(12):2471–2484
85. Renner MC et al (2017) Synaptic plasticity through activation of GluA3-containing AMPA-receptors. *Elife* 6:e25462
86. Traynelis SF et al (2010) Glutamate receptor ion channels: structure, regulation, and function. *Pharmacol Rev* 62(3):405–496
87. Poulsen MH et al (2014) Evaluation of PhTX-74 as subtype-selective inhibitor of GluA2-containing AMPA receptors. *Mol Pharmacol* 85(2):261–268
88. Poon K et al (2011) Mechanisms of modal activation of GluA3 receptors. *Mol Pharmacol* 80(1):49–59
89. Poon K, Nowak LM, Oswald RE (2010) Characterizing single-channel behavior of GluA3 receptors. *Biophys J* 99(5):1437–1446
90. Akinshola BE et al (2003) Ethanol sensitivity of recombinant homomeric and heteromeric AMPA receptor subunits expressed in *Xenopus* oocytes. *Alcohol Clin Exp Res* 27(12):1876–1883
91. Semenov A et al (2012) Autoinactivation of the stargazin-AMPA receptor complex: subunit-dependency and independence from physical dissociation. *PLoS ONE* 7(11):e49282
92. Szymańska E et al (2017) Aryl- and heteroaryl-substituted phenylalanines as AMPA receptor ligands. *Chem Biol Drug Des* 90(6):1271–1281
93. Szymańska E et al (2017) Pharmacological characterization and binding modes of novel racemic and optically active phenylalanine-based antagonists of AMPA receptors. *Eur J Med Chem* 138:874–883
94. Coleman SK et al (2010) Ligand-binding domain determines endoplasmic reticulum exit of AMPA receptors. *J Biol Chem* 285(46):36032–36039
95. Boulter J et al (1990) Molecular cloning and functional expression of glutamate receptor subunit genes. *Science* 249(4972):1033–1037
96. Keinänen K et al (1990) A family of AMPA-selective glutamate receptors. *Science* 249(4968):556–560
97. Nakanishi N, Shneider NA, Axel R (1990) A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties. *Neuron* 5(5):569–581
98. Verdoorn TA et al (1991) Structural determinants of ion flow through recombinant glutamate receptor channels. *Science* 252(5013):1715–1718
99. Wenthold RJ et al (1996) Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. *J Neurosci* 16(6):1982–1989
100. Sans N et al (2003) Aberrant formation of glutamate receptor complexes in hippocampal neurons of mice lacking the GluR2 AMPA receptor subunit. *J Neurosci* 23(28):9367–9373
101. Zhao Y et al (2019) Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM. *Science* 364(6438):355–362
102. Wright A, Vissel B (2012) The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. *Front Mol Neurosci* 5:34
103. Rossmann M et al (2011) Subunit-selective N-terminal domain associations organize the formation of AMPA receptor heteromers. *EMBO J* 30(5):959–971
104. Greger IH, Watson JF, Cull-Candy SG (2017) Structural and functional architecture of AMPA-type glutamate receptors and their auxiliary proteins. *Neuron* 94(4):713–730
105. Hansen KB et al (2021) Structure, function, and pharmacology of glutamate receptor ion channels. *Pharmacol Rev* 73(4):298–487

106. Banke TG, Schousboe A, Pickering DS (1997) Comparison of the agonist binding site of homomeric, heteromeric, and chimeric GluR1(o) and GluR3(o) AMPA receptors. *J Neurosci Res* 49(2):176–185
107. Kristensen AS et al (2011) Mechanism of Ca²⁺/calmodulin-dependent kinase II regulation of AMPA receptor gating. *Nat Neurosci* 14(6):727–735
108. Pacheco R et al (2006) Glutamate released by dendritic cells as a novel modulator of T cell activation. *J Immunol* 177(10):6695–6704
109. Pouloupoulou C et al (2005) Modulation of voltage-gated potassium channels in human T lymphocytes by extracellular glutamate. *Mol Pharmacol* 67(3):856–867
110. Hanč P et al (2023) Multimodal control of dendritic cell functions by nociceptors. *Science* 379(6639):eabm5658
111. Hanč P et al (2023) Control of myeloid cell functions by nociceptors. *Front Immunol* 14:1127571
112. Pei W, Huang Z, Niu L (2007) GluR3 flip and flop: differences in channel opening kinetics. *Biochemistry* 46(7):2027–2036
113. Pei W et al (2009) Flip and flop: a molecular determinant for AMPA receptor channel opening. *Biochemistry* 48(17):3767–3777
114. Dawe GB et al (2019) Nanoscale mobility of the apo state and TARP stoichiometry dictate the gating behavior of alternatively spliced AMPA receptors. *Neuron* 102(5):976–992.e5
115. Nishimura S et al (2000) Stable expression of human homomeric and heteromeric AMPA receptor subunits in HEK293 cells. *Recept Channels* 7(2):139–150
116. Wang SY et al (2016) Tweaking subtype selectivity and agonist efficacy at (S)-2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propionic acid (AMPA) receptors in a small series of BnTetAMPA analogues. *J Med Chem* 59(5):2244–2254
117. Lambolez B et al (1992) AMPA receptor subunits expressed by single Purkinje cells. *Neuron* 9(2):247–258
118. Mosbacher J et al (1994) A molecular determinant for submillisecond desensitization in glutamate receptors. *Science* 266(5187):1059–1062
119. Quirk JC, Siuda ER, Nisenbaum ES (2004) Molecular determinants responsible for differences in desensitization kinetics of AMPA receptor splice variants. *J Neurosci* 24(50):11416–11420
120. Lambolez B et al (1996) Correlation between kinetics and RNA splicing of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in neocortical neurons. *Proc Natl Acad Sci U S A* 93(5):1797–1802
121. Tölle TR et al (1995) Flip and flop variants of AMPA receptors in the rat lumbar spinal cord. *Eur J Neurosci* 7(6):1414–1419
122. Tomiyama M et al (1997) Distribution of AMPA receptor subunit mRNAs in the human basal ganglia: an in situ hybridization study. *Brain Res Mol Brain Res* 46(1–2):281–289
123. Guthmann A, Herbert H (1999) In situ hybridization analysis of flip/flop splice variants of AMPA-type glutamate receptor subunits in the rat parabrachial and Kölliker-Fuse nuclei. *Brain Res Mol Brain Res* 74(1–2):145–157
124. Stine CD, Lu W, Wolf ME (2001) Expression of AMPA receptor flip and flop mRNAs in the nucleus accumbens and prefrontal cortex after neonatal ventral hippocampal lesions. *Neuropsychopharmacology* 24(3):253–266
125. Alqahtani A et al (2023) Genomics and transcriptomic alterations of the glutamate receptors in acute myeloid leukemia. *Clin Transl Sci* 16(10):1828–1841
126. Genever PG et al (1999) Expression of a functional N-methyl-D-aspartate-type glutamate receptor by bone marrow megakaryocytes. *Blood* 93(9):2876–2883
127. Hearn JI et al (2020) N-methyl-D-aspartate receptor hypofunction in Meg-01 cells reveals a role for intracellular calcium homeostasis in balancing megakaryocytic-erythroid differentiation. *Thromb Haemost* 120(4):671–686
128. Hardingham GE (2006) Pro-survival signalling from the NMDA receptor. *Biochem Soc Trans* 34(Pt 5):936–938

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.